Treatment of diffuse toxic goiter during pregnancy
We have studied an influence of diffuse toxic goiter on the flow and outcome pregnancy. 67 pregnant women with diffuse toxic goiter were examined. The group of comparison consisted of 38 pregnant women without thyroid pathology. The levels of free thyroxin, TSH, autoantibodies to TSH-receptors and autoantibodies to thyreoperoxidasis in the blood of pregnant women and umbilical cord blood and ultrasound of the thyroid gland of newborns were analyze. Pregnancy and childbirth of the women with unresolved thyrotoxicosis were more complicated by the threat of termination of pregnancy, preeclampsia, chronic placental insufficiency, preterm rupture of membranes, fetal hypotrophy and hypoxia. A high incidence of subclinical hypothyroidism (more 50%) in newborns is associated with the transplacental pass thyreostatic drugs. Subclinical hyperthyroidism in 17% of newborns should be associated with the transplacental transition from the mother to the fetus of autoantibodies to TSH-receptors.